The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan - Product Development Opportunities and Business Expansion Strategies for
17 Feb 2011 • by Natalie Aster
New York – The study " The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan - Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers " by Venture Planning Group is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses.
The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.
Report Details:
Published: June 2010
Pages: 1115
Price: US$ 29,400.00
Report Sample Abstract
In early 2010, Roche plans to add STAT capability to its Cobas e 601 immunoassay analyzer. This will result in a nine-minute turnaround time. The Cobas 8000 integrated analyzer series are the Cobas c701 and Cobas c502 analyzers. The Cobas c701 will offer photometric throughput of up to 2,000 results per hour and include 70 reagent positions. The Cobas c502 has a throughput of up to 600 results per hour, and can run 60 different assays. The 8000 series immunoassay module is the Cobas e602.
The company is releasing first the 8000 outside the U.S. and domestically in 2010. For lower-volume labs the Cobas c311 analyzer, introduced in 2009, is a stand alone chemistry solution with STAT assay capability and the same reagents and user interface the Cobas 6000 series.
Caroline Liquid Chemistries BioLis 24i bench-top chemistry system, introduced in summer of 2008, features a menu of more than 100 tests, a no-pretreat HbA1c that correlates 1:1 to high-pressure liquid chromatography, and a water system that eliminates the need for water cubes that have to be transported and stored. The BioLis 12i is a low-volume chemistry analyzer, which is pending FDA 510 (k) clearance.
Randox Laboratories has added cystatin C and SLDL assays to its RX Imola bench-top analyzer’s test menu. The company has laso added a drugs-of-abuse test panel, which now includes assays for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ecstasy, EDDP, methadone, and opiates.
The Awarenesss Technology ChemWell series of analyzers includes the 2902 and 2910. The 2902 is a chemistry analyzer, while the 2910 has the added benefits of being an EIA-capable analyzer along with the chemistry functions. Awareness’ latest model is the Stat Fax-4500 compact chemistry analyzer for low-volume labs, which has touchscreen technology, onboard curve-fitting software, and an optional flow-cell feature.
Also in 2009, Beckman Coulter introduced three new integrated chemistry/immunoassay system solutions: the UniCel DxC 660i, UniCel DxC 680i, and UniCel DxC 860i Synchron Access. Each system is configured to meet a different level of throughput and features Beckman Coulter’s automated closed-tube aliquotting and sampling ClozCap technology, which free technologists from the labor-intensive tasks of decapping, recapping, and sorting samples manually.
Fujirebio markets approximately 50 products in over 80 countries. In Japan, the company's products are sold by a dedicated sales organization of over 300 representatives located in 12 sales offices nationwide. The company also owns Special Reference Laboratories, the largest commercial laboratory in Japan.
Fujirebio is one of the major suppliers of tumor markers in Japan. The company is selling an extensive portfolio of tests, including CEA, AFP, CA 15-3, CA 19-9, CA 125 II, CA 242, Beta-2 Microglobulin, Ferritin, PSA (free, complex, total), and several others. The company is also offering the Fastec-901 automated agglutination pattern scanning system, consisting of an internal CCD TV camera, image processing software and a monitor.
Recently, Fujirebio introduced the HE4 (WFDC2) biomarker, which belongs to the family of whey acidic four-disulfide core (WFDC) proteins. The HE4 is used for monitoring the recurrence or progressive disease in patients with epithelial ovarian cancer. Another recent addition to the company’s product portfolio is the MESOMARK ELISA assay for monitoring patients with epithelioid and biphasic malignant mesothelioma.
More information can be found in the report “The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan - Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers ” by Venture Planning Group .
To order the report or ask for sample pages contact [email protected]
Contacts
MarketPublishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
www.marketpublishers.com
Analytics & News
